

Roberto Bortolus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3002509/publications.pdf>

Version: 2024-02-01

47
papers

1,444
citations

471509

17
h-index

315739

38
g-index

50
all docs

50
docs citations

50
times ranked

1796
citing authors

#	ARTICLE	IF	CITATIONS
1	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. <i>Medical Oncology</i> , 2021, 38, 72.	2.5	6
2	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td</i> 2021, 38, 527-537.	3.3	14
3	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). <i>PLoS ONE</i> , 2019, 14, e0224151.	2.5	8
4	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2082.	4.1	6
5	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	2.2	69
6	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5</i>	3.3	14
7	Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 508-515.	3.9	7
8	²²³ Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. <i>Tumori</i> , 2018, 104, 128-136.	1.1	14
9	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 122.	2.4	24
10	Weekly cabazitaxel in elderly patients (EP) with metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel treatment: WeCabE, a phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 300-300.	1.6	1
11	Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 322-322.	1.6	1
12	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 165-172.	2.9	26
13	MP53-14 MULTIMODAL TREATMENT FOR HIGH-RISK PROSTATE CANCER WITH HIGH-DOSE INTENSITY-MODULATED RADIATION THERAPY, CONCURRENT INTENSIFIED-DOSE DOCETAXEL AND LONG-TERM ANDROGEN DEPRIVATION THERAPY AFTER RADICAL PROSTATECTOMY AND LYMPHADENECTOMY: RESULTS OF A PROSPECTIVE PHASE II TRIAL... <i>Journal of Urology</i> , 2017, 197, .	0.4	0
14	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 43-51.	4.4	28
15	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. <i>Oncotarget</i> , 2017, 8, 22863-22875.	1.8	9
16	Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. <i>BJU International</i> , 2016, 117, 867-873.	2.5	23
17	Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOING Treatment for Prostate canCER (CHOICE) Study. <i>Urology</i> , 2016, 96, 165-170.	1.0	21
18	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. <i>Tumor Biology</i> , 2016, 37, 9855-9863.	1.8	15

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	2.4	8
20	Towards the multidisciplinary management of prostate cancer patients: the PerSTEP Project experience. <i>Annals of Oncology</i> , 2015, 26, vi57.	1.2	0
21	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	2.4	43
22	Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. <i>Radiation Oncology</i> , 2014, 9, 24.	2.7	17
23	The German Hodgkin Study Group Stratification Scheme for Newly Diagnosed Hodgkin Lymphoma Is Useful for Predicting Outcome of Patients Receiving Radiation Therapy After Autologous Self Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S671.	0.8	0
24	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014, 32, 92-92.	1.6	2
25	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013, 31, 189-189.	1.6	0
26	Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. <i>Journal of Neuro-Oncology</i> , 2012, 107, 191-196.	2.9	40
27	7059 POSTER Incidence and Outcomes of Brain and Meningeal Metastases (BMm) in Patients With Castration-resistant Prostate Cancer (CRPC) in the Era of Docetaxel (DOC). <i>European Journal of Cancer</i> , 2011, 47, S503.	2.8	0
28	220 ADJUVANT OR SALVAGE RADIOTHERAPY? FIVE YEAR RESULTS OF THE "AIRO NATIONAL WORKING GROUP ON PROSTATE RADIOTHERAPY" MULTICENTER PROSPECTIVE STUDY. <i>European Urology Supplements</i> , 2011, 10, 91.	0.1	0
29	499 oral SALVAGE OR ADJUVANT? 5Y-RESULTS OF THE "AIRO NATIONAL WORKING GROUP ON PROSTATE RADIOTHERAPY" MULTICENTER PROSPECTIVE STUDY. <i>Radiotherapy and Oncology</i> , 2011, 99, S202.	0.6	1
30	A phase II noncomparative study of neoadjuvant (NA) chemohormone therapy (CHT), radical prostatectomy (RP), and postoperative radiotherapy (RT) in locally advanced (LA) high-risk prostate cancer (HRPC): A monoinstitutional 6-year experience with two NA CHT regimens. <i>Journal of Clinical Oncology</i> , 2009, 27, e16091-e16091.	1.6	0
31	Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 19-30.	0.8	71
32	What elderly cancer patients want to know? Differences among elderly and young patients. <i>Psycho-Oncology</i> , 2007, 16, 365-370.	2.3	41
33	[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1387-1398.	6.4	304
34	Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC Tj ETQq0,0,0 rgt, JOverlock	10,8	22
35	Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2003, 348, 2396-2406.	27.0	301
36	Hepatitis C virus and non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 1996, 94, 544-550.	2.5	171

#	ARTICLE	IF	CITATIONS
37	Solitary Thyroid Metastasis from a Renal Cell Carcinoma Diagnosed and Treated 12 Years before: A Case Report. <i>Tumori</i> , 1995, 81, 450-453.	1.1	3
38	Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. <i>Cancer</i> , 1994, 74, 978-984.	4.1	20
39	Results of Three Consecutive Combined Treatments for Malignant Gliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 437-443.	1.3	8
40	Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. <i>Radiotherapy and Oncology</i> , 1992, 23, 241-244.	0.6	17
41	Hyperthermia in Clinical Practice: Preliminary Results and Current Problems in the Treatment of 21 Patients. <i>Tumori</i> , 1992, 78, 262-265.	1.1	1
42	Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1991, 41, 206-211.	1.4	7
43	Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma. <i>Tumori</i> , 1991, 77, 61-64.	1.1	18
44	Feasibility of Total Body Irradiation in Chronic Lymphocytic Leukemia and Low-Grade Non-Hodgkin's Lymphomas. <i>Cancer Investigation</i> , 1991, 9, 403-407.	1.3	9
45	Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer. <i>Tumori</i> , 1989, 75, 47-52.	1.1	7
46	Multiple fraction per day radiation therapy for inoperable esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 14, 855-860.	0.8	17
47	Accelerated split course regimen in the treatment of brain metastases. <i>Radiotherapy and Oncology</i> , 1988, 12, 39-44.	0.6	12